ERCC1 and anemia: ERCC1 rs11615 was associated with an increased risk of grade 3-4 anemia in 290 ovarian cancer patients (OR = 1.61; 95% CI: 1.04–2.50; p = 0.031) (Lambrechts et al., 2015) and 437 NSCLC patients (OR = 2.230; 95% CI: 1.041–4.775; p = 0.039) (Zheng et al., 2017).